Toolkit/logic DNAzyme system

logic DNAzyme system

RNA Element·Research·Since 2025

Also known as: C1/C2 and endogenous lncRNA logic DNAzyme system, C1/C2 DNAzyme system

Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

An ingenious logic DNAzyme system consists of Chain 1 (C1)/Chain 2 (C2) and endogenous lncRNA is designed.

Usefulness & Problems

Why this is useful

This logic DNAzyme system is built from C1 and C2 chains and endogenous lncRNA. After release, the chains self-assemble with endogenous lncRNA to form a functional DNAzyme that targets PD-L1 mRNA for silencing.; logic-gated gene silencing; PD-L1 mRNA targeting

Source:

This logic DNAzyme system is built from C1 and C2 chains and endogenous lncRNA. After release, the chains self-assemble with endogenous lncRNA to form a functional DNAzyme that targets PD-L1 mRNA for silencing.

Source:

logic-gated gene silencing

Source:

PD-L1 mRNA targeting

Problem solved

It provides a conditional nucleic-acid silencing module aimed at PD-L1 mRNA within the combined immunotherapy design.; adds endogenous-lncRNA-dependent control to DNAzyme function; enables PD-L1 mRNA silencing as part of a combined immunotherapy strategy

Source:

It provides a conditional nucleic-acid silencing module aimed at PD-L1 mRNA within the combined immunotherapy design.

Source:

adds endogenous-lncRNA-dependent control to DNAzyme function

Source:

enables PD-L1 mRNA silencing as part of a combined immunotherapy strategy

Problem links

adds endogenous-lncRNA-dependent control to DNAzyme function

Literature

It provides a conditional nucleic-acid silencing module aimed at PD-L1 mRNA within the combined immunotherapy design.

Source:

It provides a conditional nucleic-acid silencing module aimed at PD-L1 mRNA within the combined immunotherapy design.

enables PD-L1 mRNA silencing as part of a combined immunotherapy strategy

Literature

It provides a conditional nucleic-acid silencing module aimed at PD-L1 mRNA within the combined immunotherapy design.

Source:

It provides a conditional nucleic-acid silencing module aimed at PD-L1 mRNA within the combined immunotherapy design.

Published Workflows

Spatiotemporally delivery of Cas9 ribonucleoprotein/DNAzyme logic systems using near-infrared upconversion nanomachine for precise immunotherapy.

2025

Objective: Develop a spatiotemporally controlled theranostic nanomachine that co-delivers Cas9 RNP and a logic DNAzyme system for precise cancer immunotherapy and gene therapy.

Why it works: The abstract states that the nanomachine carries Cas9 RNP and a UV-responsive DNA construct, releases Mn2+ in the tumor microenvironment to aid endosomal escape and activate cGAS-STING signaling, and uses near-infrared irradiation to dissociate the complex so Cas9 RNP and DNAzyme functions are activated in a controlled manner.

Ptpn2 gene editingPD-L1 mRNA silencingcGAS-STING activationendosomal escapenear-infrared activationupconversion nanoparticle deliverylogic-gated DNAzyme assemblyCas9 RNP delivery

Steps

  1. 1.
    Load Cas9 RNP and UV-responsive C1-PC linker-C2 onto manganese-modified upconversion nanoparticles with hyaluronic acid coatingdelivery platform and light-responsive nucleic-acid payload

    Create a co-delivery nanomachine carrying both CRISPR and DNAzyme precursor modules.

    Payload loading and coating are required before tumor delivery and later stimulus-responsive release can occur.

  2. 2.
    Tumor-microenvironment-triggered Mn2+ releasetumor-responsive delivery harness

    Enable endosomal escape, cGAS-STING activation, and T1-magnetic resonance imaging after reaching the tumor microenvironment.

    The abstract states these Mn2+-dependent functions occur upon reaching the tumor microenvironment and prepare the system for intracellular activity.

  3. 3.
    Near-infrared irradiation triggers dissociation of the Cas9 RNP/C2P complexNIR-responsive release system

    Spatiotemporally activate release of Cas9 RNP and DNAzyme precursor components.

    The abstract explicitly places near-infrared-triggered dissociation after tumor localization, enabling controlled activation at the target site.

  4. 4.
    Cas9 RNP enters the nucleus and edits Ptpn2Cas9 RNP delivery system

    Execute gene editing of Ptpn2 as one arm of the therapeutic mechanism.

    Nuclear gene editing follows optical release of Cas9 RNP from the nanomachine.

  5. 5.
    C1 and C2 self-assemble with endogenous lncRNA into a functional DNAzyme targeting PD-L1 mRNAlogic-gated silencing module

    Form the active DNAzyme system for PD-L1 mRNA silencing.

    This assembly occurs after release of the C1/C2 components and depends on endogenous lncRNA in the target environment.

Taxonomy & Function

Primary hierarchy

Mechanism Branch

Component: A low-level RNA part used inside a larger architecture that realizes a mechanism.

Target processes

editing

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator

It requires the C1 and C2 chain components and the presence of endogenous lncRNA in the target environment. In this paper it is also coupled to the nanomachine delivery system.; requires Chain 1 and Chain 2 components; requires endogenous lncRNA for self-assembly into the functional DNAzyme system

The abstract does not establish that it works independently of endogenous lncRNA availability or that it broadly generalizes to other targets without redesign.; abstract does not identify the lncRNA or define sequence-level design constraints

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1mechanismsupports2025Source 1needs review

Released Mn2+ ions from the nanomachine facilitate endosomal escape, activate cGAS-STING signaling, and enable T1-magnetic resonance imaging in the tumor microenvironment.

Claim 2mechanismsupports2025Source 1needs review

Under near-infrared irradiation, the Cas9 RNP/C2P complex dissociates, releasing Cas9 RNP into the nucleus for Ptpn2 gene editing while C1/C2 chains self-assemble with endogenous lncRNA into a functional DNAzyme targeting PD-L1 mRNA.

Claim 3therapeutic effectsupports2025Source 1needs review

The combined strategy remodels the tumor microenvironment through cGAS-STING activation and dual immune checkpoint blockade, realizing tumor elimination.

Claim 4tool functionsupports2025Source 1needs review

The near-infrared upconversion theranostic nanomachine is designed to mediate precise gene therapy using CRISPR-Cas9 and DNAzyme systems.

Approval Evidence

1 source2 linked approval claimsfirst-pass slug logic-dnazyme-system
An ingenious logic DNAzyme system consists of Chain 1 (C1)/Chain 2 (C2) and endogenous lncRNA is designed.

Source:

mechanismsupports

Under near-infrared irradiation, the Cas9 RNP/C2P complex dissociates, releasing Cas9 RNP into the nucleus for Ptpn2 gene editing while C1/C2 chains self-assemble with endogenous lncRNA into a functional DNAzyme targeting PD-L1 mRNA.

Source:

therapeutic effectsupports

The combined strategy remodels the tumor microenvironment through cGAS-STING activation and dual immune checkpoint blockade, realizing tumor elimination.

Source:

Comparisons

Source-stated alternatives

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Source:

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Source-backed strengths

uses endogenous lncRNA to assemble a functional DNAzyme system; pairs with Cas9 editing in the same therapeutic platform

Source:

uses endogenous lncRNA to assemble a functional DNAzyme system

Source:

pairs with Cas9 editing in the same therapeutic platform

Compared with CRISPR/Cas9

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Shared frame: source-stated alternative in extracted literature

Strengths here: uses endogenous lncRNA to assemble a functional DNAzyme system; pairs with Cas9 editing in the same therapeutic platform.

Relative tradeoffs: abstract does not identify the lncRNA or define sequence-level design constraints.

Source:

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Compared with CRISPR/Cas9 system

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Shared frame: source-stated alternative in extracted literature

Strengths here: uses endogenous lncRNA to assemble a functional DNAzyme system; pairs with Cas9 editing in the same therapeutic platform.

Relative tradeoffs: abstract does not identify the lncRNA or define sequence-level design constraints.

Source:

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Compared with gene therapy

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Shared frame: source-stated alternative in extracted literature

Strengths here: uses endogenous lncRNA to assemble a functional DNAzyme system; pairs with Cas9 editing in the same therapeutic platform.

Relative tradeoffs: abstract does not identify the lncRNA or define sequence-level design constraints.

Source:

The abstract contrasts the combined CRISPR-Cas9 and DNAzyme approach with broader gene therapy approaches using CRISPR-Cas9 and/or DNAzyme systems.

Ranked Citations

  1. 1.
    StructuralSource 1MED2025Claim 1Claim 2Claim 3

    Seeded from load plan for claim c4. Extracted from this source document.